Taladua, Weaflare .
HRN: 23-25-09 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/25/2023
CEFUROXIME 500MG (TAB)
06/25/2023
07/02/2023
PO
500 Mg Tab
BID
G2 P2 (2002) SP NSVD W Laceration & Repair, MSAF Thinly
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes